World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
54
Citations
17652
World Ranking
3839
National Ranking
1760

Adrian Bot publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Adrian Bot sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 308 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Adrian Bot D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Adrian Bot sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 54 D-Index — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Adrian Bot is affiliated with MannKind Corporation based in the United States. Their research primarily spans the field of Medicine, with a strong concentration in Oncology and Immunology. Their work also encompasses Molecular Biology, Genetics, and Electrical and Electronic Engineering.

The scientist's research contributions focus heavily on CAR-T cell therapy, immunotherapy, and related immune responses. Key topics addressed in their publications include:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Virus-based gene therapy research
  • Integrated Circuits and Semiconductor Failure Analysis
  • Advancements in Semiconductor Devices and Circuit Design
  • Lymphoma Diagnosis and Treatment
  • Nanowire Synthesis and Applications

Adrian Bot has co-authored publications frequently with several researchers, including:

  • John M. Rossi
  • Sattva S. Neelapu
  • Caron A. Jacobson
  • Frederick L. Locke
  • Lazaros J. Lekakis

Their papers have appeared notably in specialized venues such as Blood, Journal of Clinical Oncology, Nature Medicine, Transplantation and Cellular Therapy, and Clinical Lymphoma Myeloma & Leukemia.

Selected recent papers authored or co-authored by Adrian Bot include:

  • Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma, 2020, Blood Advances
  • Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma, 2020, Nature Medicine
  • TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers, 2021, Nature Medicine
  • A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy, 2021, Cancer Discovery
  • KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results, 2021, Blood

Best Publications

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

    Frederick L Locke;Armin Ghobadi;Caron A Jacobson;David B Miklos

  • Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    Frederick L. Locke;Sattva S. Neelapu;Nancy L. Bartlett;Tanya Siddiqi

  • Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

    James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;Victoria Shi

  • Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

    Frederick L. Locke;John M. Rossi;Sattva S. Neelapu;Caron A. Jacobson

  • Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.

    John Rossi;Patrick Paczkowski;Yueh-Wei Shen;Kevin Morse

  • Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

    Jennifer N Brudno;Norris Lam;Danielle Vanasse;Yueh-Wei Shen

  • TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.

    Nisha B. Nagarsheth;Scott M. Norberg;Andrew L. Sinkoe;Sabina Adhikary

  • Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.

    James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;James C. Yang

  • Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

    Unknown

  • Autoreactive CD4+ T Cells Protect from Autoimmune Diabetes via Bystander Suppression Using the IL-4/Stat6 Pathway

    Dirk Homann;Andreas Holz;Adrian Bot;Bryan Coon

  • Antigen kinetics determines immune reactivity.

    Pål Johansen;Tazio Storni;Lorna Rettig;Zhiyong Qiu

  • A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy

    Ranjan Upadhyay;Jonathan A. Boiarsky;Gvantsa Pantsulaia;Judit Svensson-Arvelund

  • Protective Role of Gamma Interferon during the Recall Response to Influenza Virus

    Adrian Bot;Simona Bot;Constantin A. Bona

  • KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

    Bijal D Shah;Michael R Bishop;Olalekan O Oluwole;Aaron C Logan

  • Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

    Frederick L. Locke;Sattva S. Neelapu;Nancy L. Bartlett;Lazaros J. Lekakis

  • CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

    Vicki Plaks;John M. Rossi;Justin Chou;Linghua Wang

  • Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL

    Zachary J Roberts;Marc Better;Adrian Bot;Margo R Roberts

  • Plasmid Vaccination with Insulin B Chain Prevents Autoimmune Diabetes in Nonobese Diabetic Mice

    Adrian Bot;Dan Smith;Simona Bot;Anna Hughes

  • Direct intralymphatic injection of peptide vaccines enhances immunogenicity.

    P. Johansen;A. C. Häffner;F. Koch;K. Zepter

  • Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract.

    Adrian I. Bot;Thomas E. Tarara;Dan J. Smith;Simona R. Bot

  • Particulate delivery systems and methods of use

    Adrian I. Bot;Thomas E. Tarara;Jeffry G. Weers;Alexey Kabalnov

  • Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination

    Lilin Wang;Dan Smith;Simona Bot;Luis Dellamary

Frequent Co-Authors

Constantin A. Bona
Constantin A. Bona Icahn School of Medicine at Mount Sinai
John J. Rossi
John J. Rossi City Of Hope National Medical Center
James N. Kochenderfer
James N. Kochenderfer National Institutes of Health
Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Thomas M. Kündig
Thomas M. Kündig University of Zurich
Matthias von Herrath
Matthias von Herrath Diabetes Research Institute Foundation
Ian W. Flinn
Ian W. Flinn Sarah Cannon Research Institute
Antoni Ribas
Antoni Ribas University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their career options after a foundation in immunology, exploring online nursing degrees can be a strategic move. Programs like online absn programs for non nurses provide accelerated pathways for individuals with non-nursing backgrounds to quickly enter the healthcare field.

Nurse practitioners specializing in family care can advance their skills by transitioning to acute care through focused programs. Resources on how to fnp to acnp transitions offer guidance for making this critical career shift successfully.

Accelerated educational options are also available for those looking to become nurse practitioners efficiently. Finding the right accelerated fnp program allows students to balance rigorous study with personal commitments.

Understanding the job market is equally important. Salaries can vary widely depending on location, making resources that detail the dnp salary by state valuable for planning your career path and geographic preferences.

Best Scientists Citing Adrian Bot

Trending Scientists

Recently Published Articles